Skip to main content
. 2018 Oct 22;71(1):57–65. doi: 10.1002/iub.1945

Figure 2.

Figure 2

Detection of an AZ‐based system for KRAS oncoprotein degradation by RC‐ODC. (a) Mutant KRAS plasmid with the Flag tag, RC, ODC, and RC‐ODC with the Myc tag were co‐transfected into human PANC‐1 cells, and the fusion protein RC‐ODC co‐immunoprecipitated with mutant KRAS as efficiently as RC. (b) RT‐PCR was used to detect the level of KRAS mRNA in cells co‐transfected with AZ and RC‐ODC. No significant differences were observed among the groups (P > 0.05). (c) After treatment with the protein synthesis inhibitor cycloheximide (50 ug/mL), the exogenous KRAS oncoprotein level decreased more rapidly in human HEK 293T cells co‐transfected with RC‐ODC and AZ than in the controls. (d) The stability of the KRAS oncoprotein was evidently improved in the presence of MG‐132 (100 nmol/L).